Business Wire

CHRYSO

9.9.2020 15:12:38 CEST | Business Wire | Press release

Share
CHRYSO and SOLIDIA Partner to Deploy Ultra-low CO2 Concrete

CHRYSO, a world leader in construction chemicals, today announces its partnership with Solidia Technologies, a start-up inventor of revolutionary technology for green cement and concrete. The two companies will collaborate to improve the sustainability performance and material properties of Solidia® ultra-low CO2 concrete through their combined chemical expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005655/en/

The partnership is underpinned by a long-term commitment from both companies to making sustainable solutions accessible to cement and concrete producers worldwide.
Solidia® sustainable technology is already available in the precast market and used for non-reinforced concrete elements. Solidia’s unique technologies are based on a revolutionary cement chemistry that can be produced at lower energies, significantly lowering carbon emissions, and that does not hydrate but carbonates by injection of CO2 into fresh concrete. Combined, Solidia’s processes lower the carbon footprint of concrete by up to 70%, while reducing water and energy consumption. They also improve the performance and durability of concrete, which are further enhanced with new, sophisticated admixture solution.
CHRYSO draws on a solid knowledge of sustainable building materials. For more than 10 years, the company has been developing admixture solutions that allow the intensive use of alternative binders without compromising material performance.

“The development of innovative admixture solutions adapted to Solidia’s new binder, boosting the final properties of concrete, is one of our R&D works in progress. This will enable higher strengths, an improved finish of the fresh concrete, and the optimization of the curing process. Together with Solidia, we will scale the use of low CO2 concrete, helping manufacturers produce high quality precast elements,” declared Jean Mascaro, Concrete BU director of CHRYSO.

Tom Schuler, president and CEO of Solidia Technologies , said: “Incorporating CHRYSO® ’s exclusive water-reducing admixtures adapted to the specific chemistry of Solidia Concrete™, will further reduce water consumption in the curing process.”
A key objective for the start-up is to improve cement and concrete production and performance while enhancing its environmental impact. Tom Schuler added: “By cutting energy consumption during the curing process, CHRYSO will help us achieve our ambitions and reach higher levels of performance.”

This partnership paves the way for upcoming advances in CO 2 footprint reduction and new developments in sustainable chemistry. The deployment of new ultra-low C0 2 concrete will accelerate the decarbonization of the construction industry.

About the CHRYSO Group
Aimed at cement manufacturers, ready-mix concrete and precast industrials, and construction companies, CHRYSO's offer includes cement additives, concrete admixtures and Solutions for Construction Systems (waterproofing solutions, mortars, etc.). CHRYSO® solutions have won renown on the most prestigious construction sites throughout the world thanks to the group's extensive network, which includes 22 foreign subsidiaries and covers more than 100 countries through its wide network of distributors, licensees and agents. The CHRYSO group employs over 1,300 staff worldwide. Innovation, customer service, expertise and technical know-how are the CHRYSO Group's cornerstones. More info about CHRYSO: www.chryso.com

About Solidia Technolgies
Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to manufacture superior, sustainable building materials. Each year, Solidia can eliminate at least 1.5 Gt of CO₂, save 3 trillion liters of fresh water, reduce cement industry energy consumption by 67 Mt of coal, and eliminate 100 Mt of concrete waste landfill. Produced using the same raw materials and existing equipment, Solidia products are higher performing and cost less to produce than traditional concrete, and cure in less than 24 hours. Solidia offers a rapid, globally scalable response to one of the greatest threats to our planet.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye